Briggs Morrison - 26 Jun 2024 Form 4 Insider Report for Carisma Therapeutics Inc. (CARM)

Reporting relationship: Director
Issuer ticker: CARM
Reported as of: 26 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2024, 16:54:23 UTC
Prior SEC filing: 20 Jun 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Richard Morris, as Attorney-in-Fact for Briggs Morrison

Key filing fact

Briggs Morrison filed Form 4 for Carisma Therapeutics Inc. (CARM) on 27 Jun 2024.

Key facts

This page summarizes Briggs Morrison's Form 4 filing for Carisma Therapeutics Inc. (CARM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2024, 16:54.

Change

Previous filing in this sequence was filed on 20 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CARM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +19,350
Change %
Price: $0.000000
Shares after: 19,350
Date: 26 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,350
Exercise price: $1.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.